The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition
Open accessThe DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index; 31 of the 81 sources its claims cite were checked for support.
Abstract
Background: Stopping antidepressants commonly causes withdrawal symptoms, which can be severe and long-lasting. National Institute for Health and Care Excellence (NICE) guidance has been recently updated to reflect this; however, for many years withdrawal (discontinuation) symptoms were characterised as ‘usually mild and self-limiting over a week’. Consequently, withdrawal symptoms might have been misdiagnosed as relapse of an underlying condition, or new onset of another medical illness, but this has never been studied. Method: This paper outlines the themes emerging from 158 respondents to an open invitation to describe the experience of prescribed psychotropic medication withdrawal for petitions sent to British parliaments. The accounts include polypharmacy (mostly antidepressants and benzodiazepines) but we focus on antidepressants because of the relative lack of awareness about their withdrawal effects compared with benzodiazepines. Mixed method analysis was used, including a ‘lean thinking’ approach to evaluate common failure points. Results: The themes identified include: a lack of information given to patients about the risk of antidepressant withdrawal; doctors failing to recognise the symptoms of withdrawal; doctors being poorly informed about the best method of tapering prescribed medications; patients being diagnosed with relapse of the underlying condition or medical illnesses other than withdrawal; patients seeking advice outside of mainstream healthcare, including from online forums; and significant effects on functioning for those experiencing withdrawal. Discussion: Several points for improvement emerge: the need for updating of guidelines to help prescribers recognise antidepressant withdrawal symptoms and to improve informed consent processes; greater availability of non-pharmacological options for managing distress; greater availability of best practice for tapering medications such as antidepressants; and the vital importance of patient feedback. Although the patients captured in this analysis might represent medication withdrawal experiences that are more severe than average, they highlight the current inadequacy of health care systems to recognise and manage prescribed drug withdrawal, and patient feedback in general.
Overview
CoChat Summary
TL;DR
This qualitative analysis of 158 patient accounts submitted to Scottish and Welsh parliamentary petitions describes antidepressant withdrawal as frequently unrecognised by clinicians, leading to misdiagnosis as relapse or new medical conditions and to patients seeking help outside mainstream care. Respondents reported lack of information about withdrawal, severe symptoms, and substantial functional harms.
Key findings
- In 158 respondents, 67% were initially prescribed antidepressants and 24% benzodiazepines/z-drugs; 97% were offered a prescription at initial consultation, 5% talking therapy, and 0.6% lifestyle advice.
- Among those reporting, 46% were not warned about side effects and 47% were not warned about withdrawal; 0% reported being warned about either. After dose reduction, 82% reported new symptoms and 91% described them as severe.
- 47% said doctors did not recognise symptoms as withdrawal (12% did); 25% were diagnosed with a new medical condition such as medically unexplained symptoms; 42% found doctors unhelpful and inaccurate, and 1% found them helpful. 51% sought help from unregulated, non-medical sources, most often online.
- Withdrawal impacts included 47% job loss, 82% loss of health and wellbeing, 35% financial hardship, and an average of 15 years of life impacted.
Methods
- Mixed qualitative and quantitative thematic analysis of 158 respondents to open invitations for petitions to the Scottish Parliament in 2017 and the Welsh Parliament in 2018, focused on prescribed psychotropic withdrawal, mostly antidepressants.
- Accounts were unstructured in Scotland or prompted by four questions in Wales; analysis used a “lean thinking” approach to identify failure points, with themes generated until saturation and overlaid on two patient journey maps.
- Thematic analysis was performed by AG, MB, and SL with additional support; only one researcher had personal experience of prescribed drug dependence and withdrawal and analysed 6% of the sample.
Limitations
- Stated: the cohort was a self-selected sample of petition respondents, not a formal research study; demographic and treatment characteristics were not robustly captured, many responses were “not said,” and patients with negative experiences were probably more likely to respond, so the sample may represent more severe and protracted withdrawal than average.
- Stated: there is possible confounding with benzodiazepines, z-drugs, and antipsychotics; some respondents were from outside the UK; and the long average duration of use (9.8 years) may relate to symptom severity.
- Evident from the text: percentages are based only on respondents who addressed each item, so denominators vary and missing data are substantial; there was no independent clinical validation of withdrawal symptoms or of the alternative diagnoses reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
13 Valid · 2 Not valid · 29 Not checked · 61 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“there is general consensus that withdrawal affects at least a third or a half of patients stopping antidepressants5,10”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > Introduction > Antidepressant withdrawal symptoms
What the sources say
- Supportedcites [5] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
The Incidence section reports a weighted average withdrawal rate of 55.7% across 14 studies. The Discussion likewise concludes that more than half (56%) of antidepressant users experience withdrawal, supporting the cited estimate of at least a third or a half. (LLM, conf=0.92)
- Disputedcites [10] Jauhar S Hayes J The war on antidepressants: what we can, and can’t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav 2019; 97: 122– 125. 30732861 PMC7613096 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says withdrawal incidence has not been fully quantified; it quotes the 56% estimate from Davies and Read rather than endorsing it. In Inclusion criteria (page unavailable), Jauhar and Hayes challenge that estimate and cite excluded studies reporting rates below one-third. The paper therefore does not support a consensus that withdrawal affects at least a third or half of patients stopping antidepressants. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Given estimates that withdrawal occurs in up to 50% of patients stopping antidepressants,5,10”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > Discussion > Failure to recognise withdrawal symptoms
What the sources say
- Disputedcites [5] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 sourceExperimental — accuracy not yet measured
Section 3.2 (Incidence) reports a weighted average withdrawal incidence of 55.7% across 14 studies, with individual estimates ranging from 27% to 86%. These figures contradict the claim’s ‘up to 50%’ ceiling. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [10] Jauhar S Hayes J The war on antidepressants: what we can, and can’t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav 2019; 97: 122– 125. 30732861 PMC7613096 sourceExperimental — accuracy not yet measured
The Introduction reports that Davies and Read estimated withdrawal in 56% of antidepressant users, which supports the existence of an estimate near half. But it does not give an ‘up to 50%’ estimate: the paper says incidence has not been fully quantified and, in Inclusion criteria, questions the methods used to calculate the reported rate. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“there is evidence to suggest that patients who have withdrawn from antidepressants can experience symptoms that last for months, and, sometimes, for years.5,15,16”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > Introduction > Antidepressant withdrawal symptoms
What the sources say
- Supportedcites [5] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
Section 3.4 (Duration) reports withdrawal symptoms lasting at least two months for some respondents, at least one year for others, and more than three years for some. The Discussion also concludes that withdrawal can last several months and beyond. The supplied passages do not specify page numbers. (LLM, conf=0.94)
- Supportedcites [15] Stockmann T Odegbaro D Timimi S, et al SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med 2018; 29: 175– 180. 29758951 source
The Discussion reports withdrawal symptoms lasting months among SSRI and SNRI users, and at least two years for 25% of the SSRI users studied. The Limitations note that these were self-reports from a withdrawal-support website and cannot establish how common such durations are among all antidepressant users; the citing sentence makes no prevalence claim. (LLM, conf=0.93)
- Not checked yetcites [16] Davies J Regina P Montagu L All-party parliamentary group for prescribed drug dependence. Antidepressant withdrawal: a survey of patients’ experience by the all-party parliamentary group for prescribed drug dependence. APPG, 2018.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has also been noted in several reviews of antidepressant withdrawal symptoms that such reactions can be mistaken for relapse of the underlying condition for which the antidepressant was originally prescribed,18–20”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > Introduction > Mistaking withdrawal for relapse or another medical condition
What the sources say
- Supportedcites [18] Haddad PM Anderson IM Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007; 13: 447– 457. source
The ‘Antidepressant discontinuation symptoms’ section explicitly says discontinuation symptoms may be diagnosed as a relapse or recurrence of the underlying affective illness. The ‘Nature of symptoms’ section also gives examples involving depression and other psychiatric disorders. (LLM, conf=0.95)
- Partly supportedcites [19] Young A Haddad P Discontinuation symptoms and psychotropic drugs control of meningococcal disease in West Africa. Lancet 2000; 355: 1184– 1185. 10791402 sourceExperimental — accuracy not yet measured
In the “Discontinuation symptoms and psychotropic drugs” section (page not given), the paper says antidepressant discontinuation symptoms can be misdiagnosed, leading to inappropriate treatment. It does not specify that they can be mistaken for relapse of the condition for which the antidepressant was prescribed. (LLM, conf=0.84)
- Supportedcites [20] Hengartner MP How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychopharmacol 2020; 10: 2045125320921694. 32435449 PMC7225779 source
The ‘Withdrawal confounding in relapse prevention trials’ section explicitly says that withdrawal symptoms can be misdiagnosed as depression relapse. The claim accurately paraphrases that point for antidepressants prescribed for depression. (LLM, conf=0.94)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As a consequence of the minimisation of their withdrawal effects, as well as a number of their other side effects (perhaps reflected in the infrequency with which GPs discuss these issues with patients), antidepressants have also been regarded as more safe that is warranted by existing data.42–45”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > Discussion > Initial prescription
What the sources say
- Partly supportedcites [42] Middleton H Moncrieff J ‘They won’t do any harm and might do some good’: time to think again on the use of antidepressants? Br J Gen Pract 2011; 61: 47– 49. 21401992 PMC3020050 sourceExperimental — accuracy not yet measured
Our copy supports the substance of the perception claim: the INTRODUCTION closes by urging reexamination of 'the widely-held aphorism that drug treatment "won't do any harm and might do some good"', the 'How this fits in' box refers to the 'undoubtedly harmful consequences of prescription', the Abstract states the uncertain benefits are 'unlikely to outweigh the risks', and IMPLICATIONS lists side effects (sexual effects, drowsiness, emotional flattening, restlessness, occasional increased suicidal impulses) that 'assume greater significance if the benefits of treatment are uncertain'. However, the specific causal mechanism the citing sentence attributes — minimisation of withdrawal effects — is absent: no passage in our copy discusses withdrawal, discontinuation or abstinence symptoms (searched: withdrawal effects, discontinuation, dependence, stopping antidepressants, rebound). The claim also rests on a citation cluster (42–45), so this source covers only the general overestimation-of-safety point, not the withdrawal-minimisation element. (LLM, conf=0.75)
- Not checked yetcites [43] Warren JB The trouble with antidepressants: why the evidence overplays benefits and underplays risks — an essay by John B Warren. BMJ. Epub ahead of print 3 9 2020 DOI: 10.1136/bmj.m3200. 32883743 source
- Not checked yetcites [44] Moncrieff J Against the stream: antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants. Psychiatrist 2018; 42: 42– 44. PMC6001865 29388527
- Not checked yetcites [45] Bet PM Hugtenburg JG Penninx BWJH, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol 2013; 23: 1443– 1451. 23726508
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
47 more claims · 7 with their cited sources checked
Create a free account to see all 105 claims and to verify the 50 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients have also reported that their withdrawal symptoms were often ignored, misattributed to recurrence of the conditions for which the BZD was initially prescribed, or misdiagnosed as another condition.128,200”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients have reported difficulty finding knowledgeable providers for BZD tapering.128,200”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that in both clinical research and practice, protracted and persistent withdrawal symptoms are frequently misdiagnosed as a relapse of the primary mental health condition (typically depression) or new emergent mental disorders (Cosci et al., 2024; Guy et al., 2020; Hengartner and Plöderl, 2021)”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Guy et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > References
“Scottish Parliamentary Petition PE01561”
§ The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition > References
“http://www.parliament.scot/GettingInvolved/Petitions/PE01651”
Citations
Cites
Using thematic analysis in psychology
Braun, V., & Clarke, V. (2006) · Qualitative Research in Psychology · doi:10.1191/1478088706qp063oa · Cited by 194,414
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Priest, R. G., Vize, C., Roberts, A., Roberts, M., & Tylee, A. (1996) · BMJ · doi:10.1136/bmj.313.7061.858 · Cited by 385
Kocalevent, R.-D., Hinz, A., & Brähler, E. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-91 · Cited by 307
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Research works printed but not linked: 2
- Royal College of Psychiatrists. Position statement on antidepressants and depression. London: Royal College of Psychiatrists, 2019.
- National Institute for Health and Care Excellence. Depression in adults: recognition and management. (NICE Guideline 90). London: NICE, 2009. 31990491
Cited by
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Self-citationEstimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
Self-citation(2022) · doi:10.1192/bja.2021.62 · Cited by 73
“There has been no systematic study of how often this misdiagnosis might occur in clinical practice but it is widely reported by patients (Guy 2020).”
Self-citationFramer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 81
“…of psychedelics is their relatively low potential for addiction and physical side effects, rendering them potentially superior to several current pharmacological treatments for mental health care (Read and Williams 2018, Davies et al. 2019, Jauhar et al. 2019, Guy et al. 2020, Lewis 2021).”
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
“Variables collected were: (1) age (in years), (2) sex, (3) type of medication and duration of use prior to tapering, (4) number of attempts to stop medication before using tapering strips, (5) severity of withdrawal symptoms during previous discontinuation attempts without tapering strips on a 1–7 Likert scale (‘Did y…”
BackgroundHorowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Self-citationChiappini, S., Vickers‐Smith, R., Guirguis, A., Corkery, J., Martinotti, G., & Schifano, F. (2022) · Pharmaceuticals · doi:10.3390/ph15050565 · Cited by 40
“Current findings, suggesting high levels of paroxetine-related dependence/withdrawal issues in comparison with remaining SSRIs, are consistent with previous literature suggestions [8,27,30,39,71].”
ResultRead, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30
Self-citation‘Never change a winning team’: GPs’ perspectives on discontinuation of long-term antidepressants
Leeuwen, E. V., Anthierens, S., van Driel, M., Sutter, A. D., van den Branden, E., & Christiaens, T. (2021) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2021.2006487 · Cited by 30
“A recent study showed this lack of initiative and support from the doctor can result in a cyclic process of patients stopping and restarting on their own and/or leading to help-seeking outside mainstream health care (such as online fora) [25,26].”
BackgroundDavies, J., Cooper, R. E., Moncrieff, J., Montagu, L., Rae, T. C., & Parhi, M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107143 · Cited by 30
Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence
Crowe, M., Inder, M., & McCall, C. (2022) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12850 · Cited by 32
“…hypothesis proposes that people with depression have depleted concentrations of serotonin, norepinephrine and dopamine, however, more recent research suggests that depression is unlikely to have a single cause such as this (Harrington, 2019) and is better described in vulnerability- stress models.”
BackgroundThe need for antidepressant withdrawal support services: Recommendations from 708 patients
Read, J., Lewis, S., Horowitz, M., & Moncrieff, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115303 · Cited by 24
“A smaller (n = 158) British analysis of submissions to parliament (Guy et al., 2020) found: ’… . a lack of information given to patients about the risk of antidepressant withdrawal; doctors failing to recognise the symptoms of withdrawal; doctors being poorly informed about the best method of…”
BackgroundSelf-citationCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
“Protracted withdrawal symptoms can have a significant negative impact with loss of jobs, friends, homes and even suicidality [15, 16].”
BackgroundSelf-citationJohnson, C. F. A., Maxwell, M., Williams, B., Dougall, N. J., & MacGillivray, S. A. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000017 · Cited by 35
Moncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100765 · Cited by 20
“One focus of this report was on a group of patients who experience protracted withdrawal symptoms that can last for more than months and can have severe impacts on people ’ s lives (Guy et al., 2020; Hengartner et al., 2020), including both financial and personal losses.”
InfluentialSelf-citationZhao, F.-Y., Fu, Q.-Q., Kennedy, G. A., Conduit, R., Zhang, W., & Zheng, Z. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.666988 · Cited by 25
Medicinal Plants in the Treatment of Depression. II: Evidence from Clinical Trials
Moragrega, I., & Ríos, J. L. (2021) · Planta Medica · doi:10.1055/a-1517-6882 · Cited by 22
“Moreover, the UKʼs NICE (National Institute for Health and Clinical Excellence) and the Royal College of Psychiatrists recently acknowledged that withdrawal symptoms related to antidepressants can last for months or even years [129,130].”
BackgroundDiscontinuing antidepressants: Pearls and pitfalls
Zwiebel, S. J., & Viguera, A. C. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21020 · Cited by 20
“Trazodone (Deseryl) 25–50 25–400 50 (25)”
InfluentialAntipsychotic Discontinuation through the Lens of Epistemic Injustice
Speyer, H., Eplov, L. F., & Roe, D. (2024) · Community Mental Health Journal · doi:10.1007/s10597-024-01274-7 · Cited by 18
“In the worst case, doctors may unknowingly misinterpret withdrawal symptoms as signs of recurring, underlying disease processes(Guy et al., 2020).”
Boland, M., Higgins, A., Beecher, C., Bracken, P., Burn, W., Cody, A., Framer, A., Gronlund, T., Horowitz, M., Huff, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088266 · Cited by 14
Self-citationTong, H., Dong, N., Lam, C. L. M., & Lee, T. M. C. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104149 · Cited by 17
Wallis, K. A., Donald, M., Horowitz, M. A., Moncrieff, J., Ware, R. S., Byrnes, J., Thrift, K., Cleetus, M., Panahi, I., Zwar, N. A., et al. (2023) · Trials · doi:10.1186/s13063-023-07646-w · Cited by 20
“…therapy; ‘Advising’ patients that long-term use is not harmless, that withdrawal symptoms are common but often misconstrued for relapse [18, 22, 24, 25]; and that hyperbolic tapering of drug dose can minimise withdrawal symptoms [25, 27]; and ‘Assisting’ patients by providing drug-specific…”
BackgroundSelf-citationPattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Mahmood, R., Wallace, V., Wiles, N., Kessler, D. S., Button, K. S., & Fairchild, G. F. (2024) · Health Expectations · doi:10.1111/hex.13966 · Cited by 12
“18 A lack of clinical input when patients are seeking repeat prescriptions exacerbates the issue.”
BackgroundPredictors of successful discontinuation of antipsychotics and antidepressants
Lincoln, T. M., Sommer, D., Quazzola, M., Witzgall, T., & Schlier, B. (2021) · Psychological Medicine · doi:10.1017/s0033291721005146 · Cited by 13
“This makes intuitive sense: Withdrawal symptoms can include a range of symptoms (Brandt et al., 2020; Cosci & Chouinard, 2020; Davies et al., 2019; Fava et al., 2015; Guy et al., 2020) that can be misidentified as a sign of impending relapse.”
BackgroundMuhammad, N., Ullah, S. R., Nagi, T. K., & Yousaf, R. A. (2023) · Cureus · doi:10.7759/cureus.37828 · Cited by 16
“The most popular and efficient treatments for depression are anti-depressant medications [8].”
BackgroundTapering antidepressants: why do tens of thousands turn to Facebook groups for support?
White, E. (2021) · British Journal of General Practice · doi:10.3399/bjgp21x716309 · Cited by 12
Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06554-4 · Cited by 10
“(Guy et al. 2020) Moreover, disproportionality analysis can only Fig.”
Meißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04941-3 · Cited by 11
“This gap in knowledge presents a risk for inadequate treatment decisions concerning antidepressant discontinuation versus continued used [37, 44].”
BackgroundEvidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review
Moncrieff, J., Hobday, H., Sørensen, A., Read, J., Plöderl, M., Hengartner, M. P., Kamp, C. B., Jakobsen, J. C., Juul, S., Davies, J., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291725100652 · Cited by 13
“Such studies are likely to miss all but the most distinctive and severe symptoms of withdrawal due to the lack of awareness of the range of effects (Guy et al., 2020).”
Self-citationMcDonald, S., Wallis, K. A., Horowitz, M. A., Mann, E., Le, V., & Donald, M. (2023) · British Journal of General Practice · doi:10.3399/bjgp.2023.0269 · Cited by 9
“Interviews were analysed in a series of four tranches, which included interviews 1–4, interviews 5–7, interviews 8–11, and then interviews 12–14.”
Self-citationRennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8
“…misdiagnosed as a relapse of the primary mental health condition (typically depression) or new emergent mental disorders (Cosci et al. , 2024; Guy et al. , 2020; Hengartner and Plöderl, 2021), the latter being specifically embedded in the concept of persistent post-withdrawal disorders…”
Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse
Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542437 · Cited by 7
Self-citationMeißner, C., Meyrose, A., & Nestoriuc, Y. (2024) · British Journal of General Practice · doi:10.3399/bjgp.2023.0020 · Cited by 14
Shapiro, B. B., Kramer, E. N., Khoury, D., & Preda, A. (2023) · Pharmacopsychiatry · doi:10.1055/a-2078-4593 · Cited by 6
“Patients often report receiving little education about the risk of withdrawal from their providers [11], in part because of deficiencies in provider knowledge and clinical guidance [12, 21, 22].”
BackgroundInfluentialFour research papers I wish my GP had read before prescribing antidepressants
Lewis, S. (2021) · British Journal of General Practice · doi:10.3399/bjgp21x716321 · Cited by 5
Self-citationTrazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability
Goldberg, J. F., Steinman, M. Q., & Stahl, S. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101127 · Cited by 7
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Wand, T. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2476156 · Cited by 6
“…shock-like sensations, diarrhoea, headaches, muscle spasms and tremors, agitation, sweating and irritability are also commonly reported and are clearly different to the symptoms for which the drug was prescribed in the first place (Davies & Read, 2019; Guy et al., 2020; Horowitz & Wilcock, 2022).”
Blair, L. J., Heydon‐Hatchett, V., Davies, G., Guy, A., & Davies, J. (2021) · Counselling and Psychotherapy Research · doi:10.1002/capr.12403 · Cited by 5
“Some people taking these drugs in the long term may be doing so partly because they feel unable to stop them due to withdrawal effects (Guy et al., 2020).”
BackgroundSelf-citationMoncrieff, J., Jakobsen, J. C., & Bachmann, M. O. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111743 · Cited by 4
Antidepressant discontinuation and the role of the pharmacist
Geen, C. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231188340 · Cited by 3
“Withdrawal or relapse? It is important to distinguish withdrawal symptoms from a relapse of anxiety or depression, as misdiagnosis of relapse (rather than withdrawal) can result in patients remaining on antidepressants longer than clinically necessary.(3,6) Given the overlap between withdrawal symptoms and symptoms of…”
BackgroundLeeuwen, E. V., Mehuys, E., Johnson, C. F. A., Keyzer, A.-S. D., Boussery, K., & Christiaens, T. C. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251333977 · Cited by 6
“23 Qualitative research suggests that GPs recognize community pharmacists as potential allies in the antidepressant discontinuation process, 24–26 similar to their role with other medicines.”
Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives
Silvernail, C. M., & Wright, S. L. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02055-y · Cited by 3
“In fact, only two published [11, 34] and two unpublished [35, 36] qualitative surveys of long-term BZD-affected individuals have been identified.”
BackgroundFrom Deinstitutionalization to Deprescribing and Beyond
Miller, R. A., & Pavlo, A. J. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108951760.011 · Cited by 2
A case report on elderly psychotic-like symptoms caused by antidepressant discontinuation
Tsai, L.-H., & Lin, J. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.02.014 · Cited by 3
Mobile phone applications to support psychotropic tapering: a scoping review protocol
Boland, M., Higgins, A., Doherty, G. J., Sheaf, G., Framer, A., & Cadogan, C. A. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13501.2 · Cited by 2
“While the frequency and severity of withdrawal symptoms are difficult to ascertain, their rate of occurrence is potentially more common than reported due to the potential for misdiagnosis as an emergence or recurrence of a mental health problem 27,28 .”
do Amaral, L. H., & Marzal, J. (2023) · The International Library of Bioethics · doi:10.1007/978-3-031-22891-9_2 · Cited by 1
Colman, L., Delaruelle, K., & Bracke, P. (2025) · Frontiers in Sociology · doi:10.3389/fsoc.2025.1204794 · Cited by 2
False reassurances based on inadequate data not helpful
Horowitz, M. A., Hengartner, M. P., Plöderl, M., & Moncrieff, J. (2025) · Psychological Medicine · doi:10.1017/s0033291725102092 · Cited by 1
“Furthermore, numerous patient reports testify to the potentially severe nature of withdrawal symptoms, which can sometimes be disabling, leading to job loss, relationship breakdown, and physical accidents (Guy, Brown, Lewis, & Horowitz, 2020; Moncrieff, Read, & Horowitz, 2024).”
Self-citationHyperbolic tapering of antidepressants: where are we now?
Horowitz, M. A., & Wilcock, M. (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000065 · Cited by 1
“8 Similar protracted withdrawal syndromes are recognised for most classes of psychiatric medications.”
Self-citationRanwala, R. A. D. L. M. K., Roughead, E. E., Calabretto, J., & Andrade, A. Q. D. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70267 · Cited by 5
Maviglia, M. A., Cooeyate, N. J., Hume, D., & Guerra, L. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00793 · Cited by 1
Beste, C., Stock, A., Colzato, L. S., Zhang, W., & Walter, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1520-4784 · Cited by 2
“As a consequence many, if not most, patients are not informed about this possible consequence of discontinuation when starting their antidepressant medication [30, 31] 1 .”
BackgroundStacy, M. A., & Davidson, C. A. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108951760.009
The problem of antidepressant withdrawal: Evolving knowledge landscapes and changing power dynamicsPreprint
Dunleavy, D. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/jzwya
Komalasari, R. (2023) · Advances in human services and public health (AHSPH) book series · doi:10.4018/978-1-7998-9652-4.ch008 · Cited by 1
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Safe Deprescribing of Benzodiazepines and Z‐drugs
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg003
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Safe Deprescribing of Gabapentinoids
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg004
Book review:The Maudsley Deprescribing Guidelines
Brown, M. (2024) · British Journal of General Practice · doi:10.3399/bjgp24x739209
Self-citationWinter, G. (2025) · Journal of Prescribing Practice · doi:10.12968/jprp.2025.0085
Les manifestations cliniques du sevrage après arrêt des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00002-9
La décision d’arrêter de prendre des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00005-4
Shanker, M., Choi, J., & Weisse, C. S. (2025) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091251381304
“12 Caregivers frequently administer comfort medications such as liquid morphine, lorazepam, and haloperidol to manage a range of distressing symptoms.”
Kamaljeet, Vijukumar, A., Shahi, A., Kumar, A., & Bhatia, R. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02103-1
“Although medical staffs are becoming more aware, ABS is missed in many patients who get therapy support mainly from case reports instead of scientific studies (Guy et al., 2020).”
Bessone, M., & Nicholl, B. I. (2026) · Journal of Public Health · doi:10.1007/s10389-026-02779-z
The “Mental Health Crisis,” a Political Issue
Bernheim, E. (2026) · The politics of mental health and illness · doi:10.1007/978-3-032-16186-4_2
Cahill, J. D., & Gallagher, K. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.010
Patient Expertise in the Doctor–Patient Interaction: The Case of Deprescribing
Gupta, S. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.028
Hengartner, M. P., Rennwald, A., Senn, O., Neuner-Jehle, S., & Horowitz, M. A. (2026) · Psychotherapy and Psychosomatics · doi:10.1159/pps/aemag002
Self-citationPsychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine
McClure, E. W. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70061
“…symptoms, leading some clinicians to misinter-pret ADS as a newly‐presenting mental disorder altogether, and leaving patients unprepared for known and predictable physiological effects from stopping treatment (Carvalho et al. 2016; Guy et al. 2020; Horowitz et al. 2025; Starcevic et al. 2015).”
Cobbaert, L., Elwyn, R., Downs, J. L., James, S., & Jackman, M. R. (2026) · PLOS mental health. · doi:10.1371/journal.pmen.0000741
“Guy et al.’s analysis of patient accounts identifies dismissal, misdiagnosis and inadequate tapering support [93].”
Metadata
- Authors
- Guy, A., Brown, M., Lewis, S., & Horowitz, M.
- Affiliations
- Psychotherapist, Secretariat Co-ordinator for the All-Party Parliamentary Group for Prescribed Drug Dependence, Basingstoke, Hampshire, UK
- Retired Psychotherapist and Co-Founder of a Patient Support Group ‘Recovery and Renewal’, Helensburgh, UK
- Lived Experience of Prescribed Drug Dependence, Cardiff, UK
- University College London (GB)
- Corresponding author
- Guy, Anne
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320967183-2045125320967183
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7659022
- OpenAlex
- W3106367973
- Semantic Scholar
- 2aa3965a8b6428d2b27651ae2828a3f9321f9c53
- Cited by
- 77
- References
- 56
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 11 · 2021: 16
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (ACF-2020-18-022)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- antidepressant withdrawal symptoms, antidepressant discontinuation, patient experience, misdiagnosis, relapse, medication tapering, informed consent, NICE guidelines, polypharmacy, benzodiazepines, online forums, patient feedback, non-pharmacological treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

